Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04701307 · ClinicalTrials.gov registry record · Phase 2

Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas

A Phase 2 study of Stage III Lung Cancer AJCC v8 and Stage IIIB Lung Cancer AJCC v8, sponsored by M.D. Anderson Cancer Center.

Active
Registry status
Phase 2
Development phase
48
Enrollment target
1
Study location

NCT04701307 is a Phase 2 study of Stage III Lung Cancer AJCC v8 and Stage IIIB Lung Cancer AJCC v8 that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 48 participants, below the 99-participant average among 40 other Stage III Lung Cancer AJCC v8 trials with a reported enrollment target (52% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04701307, a Phase 2 study of Stage III Lung Cancer AJCC v8 and Stage IIIB Lung Cancer AJCC v8, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
48 participants
Enrollment target
1
Study location

Study Summary

This phase II trial studies the effect of niraparib and dostarlimab in treating small cell lung cancer and other high-grade neuroendocrine carcinomas. Niraparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. Immunotherapy with monoclonal antibodies, such as dostarlimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving niraparib and dostarlimab may help to control the diseases.

Conditions Studied

Stage III Lung Cancer AJCC v8 Stage IIIB Lung Cancer AJCC v8 Stage IIIA Lung Cancer AJCC v8 Stage IIIC Lung Cancer AJCC v8 Neuroendocrine Carcinoma Lung Small Cell Carcinoma

Interventions

  • DRUG Niraparib
  • BIOLOGICAL Dostarlimab

Study Locations (1)

Texas

  • M D Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 48 participants
Start Date 2021-02-01
Est. Completion 2026-04-30
Phase Phase 2

Sponsor

M.D. Anderson Cancer Center

2,692 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04701307

The ClinicalTrials.gov registry entry for NCT04701307 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 99-participant average among 40 other Stage III Lung Cancer AJCC v8 trials with a reported enrollment target (52% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.

The record links to 6 conditions, with Stage III Lung Cancer AJCC v8 appearing as the primary indexed condition, and to 2 interventions - of which Niraparib is the first listed.

NCT04701307 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT04701307 about?

NCT04701307 is a clinical study titled "Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas". This phase II trial studies the effect of niraparib and dostarlimab in treating small cell lung cancer and other high-grade neuroendocrine carcinomas. Niraparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep cance...

What is the current status of trial NCT04701307?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2021-02-01. Estimated completion is 2026-04-30.

What conditions does trial NCT04701307 study?

This clinical trial studies the following conditions: Stage III Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Neuroendocrine Carcinoma.

What interventions are being tested in trial NCT04701307?

The interventions under investigation include: Niraparib (DRUG), Dostarlimab (BIOLOGICAL).

Who is sponsoring clinical trial NCT04701307?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04701307 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Stage III Lung Cancer AJCC v8

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Stage III Lung Cancer AJCC v8

All registered trials for this condition

Stage IIIB Lung Cancer AJCC v8

All registered trials for this condition

Texas

All trials with a study site in Texas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.